Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Posted: October 30, 2024 at 2:42 am

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3?), announced that it will participate in “Webinar Wednesday” hosted by Lantern Pharma on October 30, 2024.

Here is the original post:
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Related Posts